Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC Q5106
    Short Description Inj retacrit non-esrd use
    Long Description Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
    Pricing indicator 51
    Coverage code D
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 9
    Effective date 2020-01-01
    Date Added 2018-07-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    00069130510 Q5106 Inj retacrit non-esrd use RETACRIT PFIZER INC. 1000 UNITS 1 10 2 20
    00069130610 Q5106 Inj retacrit non-esrd use RETACRIT PFIZER INC. 1000 UNITS 1 10 3 30
    00069130710 Q5106 Inj retacrit non-esrd use RETACRIT PFIZER INC. 1000 UNITS 1 10 4 40
    00069130810 Q5106 Inj retacrit non-esrd use RETACRIT PFIZER INC. 1000 UNITS 1 10 10 100
    00069130904 Q5106 Inj retacrit non-esrd use RETACRIT PFIZER INC. 1000 UNITS 1 4 40 160
    00069131110 Q5106 Inj retacrit non-esrd use Retacrit PFIZER INC. 1000 UNITS 1 10 20 200
    00069131810 Q5106 Inj retacrit non-esrd use Retacrit PFIZER INC. 1000 UNITS 2 10 10 100
    59353000210 Q5106 Inj retacrit non-esrd use Retacrit VIFOR (INTERNATIONAL) LTD. 1000 UNITS 1 10 2 20
    59353000310 Q5106 Inj retacrit non-esrd use Retacrit VIFOR (INTERNATIONAL) LTD. 1000 UNITS 1 10 3 30
    59353000410 Q5106 Inj retacrit non-esrd use Retacrit VIFOR (INTERNATIONAL) LTD. 1000 UNITS 1 10 4 40
    59353001010 Q5106 Inj retacrit non-esrd use Retacrit VIFOR (INTERNATIONAL) LTD. 1000 UNITS 1 10 10 100
    59353012010 Q5106 Inj retacrit non-esrd use Retacrit VIFOR (INTERNATIONAL) LTD. 1000 UNITS 1 10 20 200
    59353022010 Q5106 Inj retacrit non-esrd use Retacrit VIFOR (INTERNATIONAL) LTD. 1000 UNITS 2 10 10 100
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 1000 UNITS
    HCPCS/CPT Billing Units 0.001
    Total doses ordered
    Billing Units 0.001

    Drug Details

    • Epoetin alfa injection products are used to treat anemia (a lower than normal number of red blood cells) in people with chronic kidney failure (condition in which the kidneys slowly and permanently stop working over a period of time). Epoetin alfa injection products are also used to treat anemia caused by chemotherapy in people with certain types of cancer or caused by zidovudine (AZT, Retrovir, in Trizivir, in Combivir), a medication used to treat human immunodeficiency virus (HIV). Epoetin alfa injection products are also used before and after certain types of surgery to decrease the chance that blood transfusions (transfer of one person's blood to another person's body) will be needed because of blood loss during surgery. Epoetin alfa injection products should not be used to decrease the risk that transfusions will be needed in people who are having surgery on their hearts or blood vessels. Epoetin alfa injection products also should not be used to treat people who are able and willing to donate blood before surgery so that this blood can be replaced in their bodies during or after surgery. Epoetin alfa injection products cannot be used in place of a red blood cell transfusion to treat severe anemia and has not been shown to improve tiredness or poor well-being that may be caused by anemia. Epoetin alfa products are in a class of medications called erythropoiesis-stimulating agents (ESAs). They work by causing the bone marrow (soft tissue inside the bones where blood is made) to make more red blood cells.